Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup
Chai Discovery, an AI drug discovery startup, has secured significant partnerships with pharmaceutical giants Eli Lilly and Pfizer. The company's advanced antibody design models, including the recently deployed Chai-3, are impressing industry leaders and driving these collaborations. Chai Discovery is also in talks to raise an additional $400 million, reflecting substantial investor confidence in the AI drug discovery sector. AI
IMPACT Accelerates AI integration in drug discovery, potentially leading to faster development of novel therapeutics.